Granata Simona, Bruschi Maurizio, Candiano Giovanni, Catalano Valeria, Ghiggeri Gian Marco, Stallone Giovanni, Zaza Gianluigi
Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Renal Unit, Department of Medicine, University/Hospital of Verona, Verona, Italy.
Kidney Blood Press Res. 2022;47(12):683-692. doi: 10.1159/000527195. Epub 2022 Oct 20.
Medullary sponge kidney (MSK) disease is a rare and neglected congenital condition typically associated with nephrocalcinosis/nephrolithiasis, urinary concentration defects, and cystic anomalies in the precalyceal ducts that, although sporadic in the general population, is relatively frequent in renal stone formers. The physiopathologic mechanism associated with this disease is not fully understood, and omics technologies may help address this gap.
The aim of this review was to provide an overview of the current state of the application of proteomics in the study of this rare disease. In particular, we focused on the results of our recent Italian collaborative studies that, analyzing the MSK whole and extracellular vesicle urinary content by mass spectrometry, have displayed the existence of a large and multifactorial MSK-associated biological machinery and identified some main regulatory biological elements able to discriminate patients affected by this rare disorder from those with idiopathic calcium nephrolithiasis and autosomal dominant polycystic kidney disease (including laminin subunit alpha 2, ficolin 1, mannan-binding lectin serine protease 2, complement component 4-binding protein β, sphingomyelin, ephrins).
The application of omics technologies has provided new insights into the comprehension of the physiopathology of the MSK disease and identified novel potential diagnostic biomarkers that may replace in future expensive and invasive radiological tests (including CT) and select novel therapeutic targets potentially employable, whether validated in a large cohort of patients, in the daily clinical practice.
髓质海绵肾(MSK)病是一种罕见且易被忽视的先天性疾病,通常与肾钙质沉着症/肾结石、尿液浓缩功能缺陷以及肾盏前导管的囊性异常有关。尽管在普通人群中为散发病例,但在肾结石患者中相对常见。与该疾病相关的生理病理机制尚未完全明确,组学技术可能有助于填补这一空白。
本综述旨在概述蛋白质组学在该罕见病研究中的应用现状。特别是,我们重点关注了我们最近的意大利合作研究结果,该研究通过质谱分析MSK患者的全尿和细胞外囊泡成分,揭示了存在一个庞大且多因素的与MSK相关的生物学机制,并鉴定出一些主要的调节性生物学元件,这些元件能够区分受这种罕见疾病影响的患者与特发性钙肾结石和常染色体显性多囊肾病患者(包括层粘连蛋白α2亚基、纤维胶凝蛋白1、甘露糖结合凝集素丝氨酸蛋白酶2、补体成分4结合蛋白β、鞘磷脂、 Ephrins)。
组学技术的应用为理解MSK病的生理病理学提供了新的见解,并鉴定出了新的潜在诊断生物标志物,这些标志物未来可能会取代昂贵且有创的放射学检查(包括CT),并确定潜在可采用的新治疗靶点,无论这些靶点是否在大量患者队列中得到验证,均可应用于日常临床实践。